Treatment of Enterococcal Pyelonephritis with Trovafloxacin and Rifampin: In Vitro-In Vivo Contrast

AUTOR(ES)

Montgomerie, J. Z.

FONTE

American Society for Microbiology

RESUMO

The in vitro bactericidal interaction of trovafloxacin and rifampin against Enterococcus spp. has indicated that antagonism occurs between these two antimicrobial agents. This drug combination was examined in vivo in rats with experimental pyelonephritis. The rats received trovafloxacin, rifampin, or both drugs. On the basis of the mean log10 CFU of Enterococcus faecalis from the kidneys, there was no evidence that trovafloxacin and rifampin were antagonistic in vivo.

Documentos Relacionados

• Desenvolvimento e validação de ensaio de dissolução para o ritonavir cápsulas utilizando correlação in vitro-in vivo
• Rifampin, ampicillin, streptomycin, and their combinations in the treatment of enterococcal pyelonephritis in rats.
• Influence of Carbon Dioxide on the MIC of Telithromycin for Streptococcus pneumoniae: an In Vitro-In Vivo Study
• Co-solvent Evaporation Method for Enhancement of Solubility and Dissolution Rate of Poorly Aqueous Soluble Drug Simvastatin: In vitro–In vivo Evaluation
• In Vitro-In Vivo Model for Evaluating the Antiviral Activity of Amprenavir in Combination with Ritonavir Administered at 600 and 100 Milligrams, Respectively, Every 12 Hours